BioSpace News Archive

Business

Titan Medical to Host Business Update Conference Call on February 6, 2018

To access the conference call, the dial-in numbers are (866) 595-8403 (U.S. and Canada toll free), and (706) 758-9979 (International).

February 7, 2018

·

2 min read

Pharm Country

World’s First Single-Port Prostatectomy Using Titan Medical’s SPORT Surgical System Completed in a Preclinical Setting

The procedure is part of the feasibility and validation studies intended to support submissions to regulators in both the United States and European Union.

February 7, 2018

·

5 min read

Business

Lundbeck Delivers Its Best Financial Results Following 10% Revenue Growth and 117% Growth in Net Profit

Revenue reached DKK 17,234 million in 2017 representing an increase of 10% (12% in local currencies) compared to 2016 .

February 7, 2018

·

2 min read

Policy

Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

Therapix announced today that it has held a pre-Investigational New Drug communication with the FDA to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome.

February 7, 2018

·

6 min read

Sinovac Holds 2017 Annual General Meeting of Shareholders

Sinovac Biotech announced today that it held its 2017 Annual General Meeting of Shareholders on Tuesday, February 6, 2018 in Beijing, PRC.

February 7, 2018

·

2 min read

Sinovac Provides Update on Going Private Transaction

Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement.

February 7, 2018

·

4 min read

Abbott’s App for FreeStyle Libre System Now Available in Europe for Both iPhone and Android

Abbott announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones2.

February 7, 2018

·

5 min read

Policy

Shaanxi Aoxing Pharmaceutical Co., Ltd. Renewed its GMP Certification

The Company received the renewed GMP certificate evidencing compliance on January 31, 2018.

February 7, 2018

·

3 min read

Policy

Galmed Granted ‘Preferred Technological Enterprise’ Status

The grant of the status means that Galmed R&D will be subject to a reduced Israeli corporate tax rate that will range between 6%-12% on any future taxable “technological income” which includes sales, licenses and royalties from its IP protected products.

February 7, 2018

·

6 min read

Drug Development

Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine

The results show markedly higher blood plasma concentrations when betahistine administered intranasally rather than orally.

February 7, 2018

·

5 min read